{"id":"zenapax-cellcept-and-prednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Gastrointestinal disturbances (diarrhea, nausea)"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Tremor, headache"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zenapax (daclizumab) is a monoclonal antibody that blocks the IL-2 receptor on T cells, preventing their activation. CellCept (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase, selectively suppressing T and B cell proliferation. Prednisolone is a corticosteroid that broadly suppresses immune responses. Together, this triple therapy provides multi-targeted immunosuppression for transplant rejection prevention.","oneSentence":"This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:36.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in renal transplant recipients"},{"name":"Prevention of acute organ rejection in other solid organ transplants"}]},"trialDetails":[{"nctId":"NCT00138970","phase":"PHASE4","title":"Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2002-01","conditions":"Renal Transplant Recipients","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Zenapax®, CellCept® and prednisolone","genericName":"Zenapax®, CellCept® and prednisolone","companyName":"University of Oslo School of Pharmacy","companyId":"university-of-oslo-school-of-pharmacy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses the immune system to prevent organ rejection after transplantation by blocking T-cell activation and proliferation while reducing corticosteroid-induced inflammation. Used for Prevention of acute organ rejection in renal transplant recipients, Prevention of acute organ rejection in other solid organ transplants.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}